Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B; HERO Study Investigators.
N Engl J Med. 2020 Jun 4;382(23):2187-2196. doi: 10.1056/NEJMoa2004325. Epub 2020 May 29.
A phase 2 study of thalidomide for the treatment of radiation-induced blood-brain barrier injury.
Cheng J, Jiang J, He B, Lin WJ, Li Y, Duan J, Li H, Huang X, Cai J, Xie J, Zhang Z, Yang Y, Xu Y, Hu X, Wu M, Zhuo X, Liu Q, Shi Z, Yu P, Rong X, Ye X, Saw PE, Wu LJ, Simone CB 2nd, Chua MLK, Mai HQ, Tang Y.
Sci Transl Med. 2023 Feb 22;15(684):eabm6543. doi: 10.1126/scitranslmed.abm6543. Epub 2023 Feb 22.
Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial.
Zhang T, Howard L, Koontz BF, Tagawa ST, Nagar H, Bitting RL, Frizzell BA, Nordquist L, Rasmussen J, Riggan C, Reyes M, Davies C, Gray SR, Newman CR, Fernandez E, Ramalingam S, Harrison MR, George DJ, Wu Y, Armstrong AJ.
Eur Urol Oncol. 2025 Apr;8(2):287-295. doi: 10.1016/j.euo.2024.06.013. Epub 2024 Jul 5.
Testosterone recovery after androgen deprivation therapy in localised prostate cancer: Long-term data from two randomised trials.
Nabid A, Carrier N, Vigneault E, Martin AG, Bahary JP, Van Nguyen T, Vavassis P, Vass S, Brassard MA, Bahoric B, Archambault R, Vincent F, Bettahar R, Duclos M, Wilke D, Souhami L.
Radiother Oncol. 2024 Jun;195:110256. doi: 10.1016/j.radonc.2024.110256. Epub 2024 Mar 27.
Erectile function preservation after salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: Five-year results of the SAKK 09/10 randomized phase 3 trial.
Zwahlen DR, Schröder C, Holer L, Bernhard J, Hölscher T, Arnold W, Polat B, Hildebrandt G, Müller AC, Martin Putora P, Papachristofilou A, Schär C, Hayoz S, Sumila M, Zaugg K, Guckenberger M, Ost P, Giovanni Bosetti D, Reuter C, Gomez S, Khanfir K, Beck M, Thalmann GN, Aebersold DM, Ghadjar P.
Clin Transl Radiat Oncol. 2024 Apr 25;47:100786. doi: 10.1016/j.ctro.2024.100786. eCollection 2024 Jul.
Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.
Nikitas J, Rettig M, Shen J, Reiter R, Lee A, Steinberg ML, Valle LF, Sachdeva A, Romero T, Calais J, Czernin J, Nickols NG, Kishan AU.
Eur Urol. 2024 Jun;85(6):517-520. doi: 10.1016/j.eururo.2024.01.021. Epub 2024 Mar 16.
Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10.
Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Stein J, Hölscher T, Gut P, Polat B, Hildebrandt G, Müller AC, Putora PM, Papachristofilou A, Schär C, Dal Pra A, Biaggi Rudolf C, Wust P, Aebersold DM, Thalmann GN; Swiss Group for Clinical Cancer Research (SAKK).
Radiother Oncol. 2018 Feb;126(2):257-262. doi: 10.1016/j.radonc.2017.10.025. Epub 2017 Nov 3.
Treatment-Related Adverse Effects in Lung Cancer Patients after Stereotactic Ablative Radiation Therapy.
Morias S, Marcu LG, Short M, Giles E, Potter A, Shepherd J, Gierlach T, Bezak E.
J Oncol. 2018 Oct 4;2018:6483626. doi: 10.1155/2018/6483626. eCollection 2018.
Association of PSA kinetics after testosterone recovery with subsequent recurrence: secondary analysis of a phase III randomized controlled trial.
Roy S, Kishan AU, Morgan SC, Martinka L, Spratt DE, Sun Y, Malone J, Grimes S, Citrin DE, Malone S.
World J Urol. 2023 Dec;41(12):3905-3911. doi: 10.1007/s00345-023-04635-1. Epub 2023 Oct 4.
Accelerated hematopoietic recovery with angiotensin-(1-7) after total body radiation.
Rodgers KE, Espinoza T, Roda N, Meeks CJ, Hill C, Louie SG, Dizerega GS.
Int J Radiat Biol. 2012 Jun;88(6):466-76. doi: 10.3109/09553002.2012.676228. Epub 2012 Apr 30.
